<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051583</url>
  </required_header>
  <id_info>
    <org_study_id>NVG AV1</org_study_id>
    <nct_id>NCT01051583</nct_id>
  </id_info>
  <brief_title>Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma</brief_title>
  <official_title>Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AL-Nour Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the efficacy of Avastin as an adjunct to Diode Laser cyclophotocoagulation in the
      treatment of Neovascular Glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: Prospective, comparative interventional case series. Method: Patients were randomly
      assigned into Group A which were treated with Diode laser cyclophotocoagulation alone,
      whereas group B received intravitreal Avastin (One milligram = 0.04mL of 25 mg/mL) in
      conjunction with the Diode Laser. The preoperative data included etiology, mean age; follow
      up period, and a full ophthalmological examination with emphasis on mean IOP, iris
      neovascularization, pain and corneal edema.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disappearance of iris neovessels</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra ocular pressure</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Neovascular Glaucoma</condition>
  <arm_group>
    <arm_group_label>Avastin , diode laser cyclophotcoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal Avastin injection in conjunction with diode laser cyclophotocoagulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diode Laser cyclophotocoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diode laser cyclophotocoagulation to control intraocular pressure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin</intervention_name>
    <description>The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).</description>
    <arm_group_label>Avastin , diode laser cyclophotcoagulation</arm_group_label>
    <arm_group_label>Diode Laser cyclophotocoagulation</arm_group_label>
    <other_name>bevacizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neovascular absolute glaucoma

          -  Painful blind eyes

        Exclusion Criteria:

          -  Neovascular glaucoma with useful vision or potential for useful vision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa A EL-Helw, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr El-Ainy hospital, Cairo university,ophthalmology departement</name>
      <address>
        <city>Cairo</city>
        <zip>11451</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr.Mostafa Aly EL-Helw assistant professor</name_title>
    <organization>Cairo university, school of medicine, ophthalmology departement. El-Nour Eye hospital</organization>
  </responsible_party>
  <keyword>Neovascular glaucoma</keyword>
  <keyword>diode laser</keyword>
  <keyword>cyclophotocoagulation</keyword>
  <keyword>Avastin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Neovascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

